跳至主要内容
临床试验/EUCTR2011-001033-16-PT
EUCTR2011-001033-16-PT进行中(未招募)1 期

Safety and Efficacy of turoctocog alfa in Prevention and Treatment of Bleeds in Paediatric Previously Untreated Patients with Haemophilia A - guardian™4

ovo Nordisk A/S0 个研究点目标入组 60 人开始时间: 2015年6月8日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

入选标准

  • - Informed consent obtained before any trial-related activities (trial-related activities are any procedure that would not have been performed during normal management of the patient)
  • - Male patients diagnosed with congenital severe haemophilia A (FVIII = 1%)
  • - Age < 6 years
  • - No prior use of purified clotting FVIII products (previous exposure, equal to or less than 5 ED to blood components, e.g. cryoprecipitate, fresh frozen plasma is accepted) including commercially available NovoEight®/Novoeight®
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 60
  • F.1.2 Adults (18-64 years) no
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • - Known or suspected allergy to hamster protein or intolerance to trial product(s) or related products
  • - Previous participation in this trial defined as withdrawal after administration of trial product
  • - Congenital or acquired coagulation disorders other than haemophilia A
  • - Any history of FVIII inhibitor
  • - Ongoing treatment or planned treatment during the trial with immunomodulatory agents (e.g. intravenous immunoglobulin (IVIG)), routine systemic corticosteroids)

研究者

相似试验

进行中(未招募)
1 期
Safety and efficacy of turoctocog alfa in prevention and treatment of bleeds in previously untreated children with Haemophilia AHaemophilia AMedDRA version: 18.0Level: LLTClassification code 10018937Term: Haemophilia ASystem Organ Class: 100000004850
EUCTR2011-001033-16-LTovo Nordisk A/S60
进行中(未招募)
1 期
Safety and efficacy of turoctocog alfa in prevention and treatment of bleeds in previously untreated children with Haemophilia AHaemophilia AMedDRA version: 19.0Level: LLTClassification code 10018937Term: Haemophilia ASystem Organ Class: 100000004850
EUCTR2011-001033-16-PLovo Nordisk A/S60
进行中(未招募)
1 期
Safety and Efficacy of turoctocog alfa in Prevention and Treatment of Bleeds in Paediatric Previously Untreated Patients with Haemophilia A - guardian™4Haemophilia AMedDRA version: 17.1Level: LLTClassification code 10018937Term: Haemophilia ASystem Organ Class: 100000004850
EUCTR2011-001033-16-HUovo Nordisk A/S60
进行中(未招募)
1 期
Safety and efficacy of turoctocog alfa inprevention and treatment of bleeds in paediatricpreviously untreated patients with Haemophilia A
EUCTR2011-001033-16-ATovo Nordisk A/S60
进行中(未招募)
1 期
Safety and efficacy of turoctocog alfa in prevention and treatment of bleeds in previously untreated children with Haemophilia AHaemophilia AMedDRA version: 20.0 Level: LLT Classification code 10018937 Term: Haemophilia A System Organ Class: 100000004850
EUCTR2011-001033-16-DKovo Nordisk A/S60